Spanish cross-cultural adaptation and validation of the Australian Pelvic Floor Questionnaire in running women

Guadalupe Molina-Torres, Marina Guallar-Bouloc, Alejandro Galán-Mercant, Martyna Kasper-Łędrzejewska, José Antonio Merchán-Baeza & Manuel Gonzalez-Sanchez

Pelvic floor dysfunctions are a wide range of disorders in the gynaecological, lower urinary and gastrointestinal tracts that affect the structure and/or function of the pelvic organs. The objective of this study was to carry out a cross-cultural adaptation and a psychometric analysis of the Spanish version of the Australian Pelvic Floor Questionnaire. Observational study divided into two main phases: (1) translation and cross-cultural adaptation and (2) psychometric tests. Women runners from all over the Spanish territory, from different federations, clubs and levels were recruited.

Participants: 424 female runners, native Spanish, over 18 years of age and who had been practicing running for more than 6 months. The instruments used in this study were the Australian Pelvic Floor Questionnaire, Female Sexual Function Index, King Health Questionnaire, Quality of Life SF-12 and EuroQol 5-D. The Spanish version of Australian Pelvic Floor Questionnaire has proven to be an understandable and easy-to-use tool. The general internal consistency of the questionnaire was 0.972 and the intraclass correlation coefficient ranged between ICC 0.596–0.960. The Spanish version of Australian Pelvic Floor Questionnaire is a valid and reliable measure that can be used clinically to assess pelvic floor dysfunctions among the female Spanish population.

Pelvic floor dysfunctions (PFDs) are a wide range of disorders in the gynaecological, lower urinary and gastrointestinal tracts that affect the structure and/or function of the pelvic organs, they are also very common after childbirth, with approximately 30% of mothers experiencing urinary incontinence (UI) and 10% anal incontinence (AI); moreover, they can also present pain and pelvic organ prolapse (POP), although it should be noted that UI is a health problem that affects the quality of life among women of all ages. On the other hand, female sexual disorders must also be considered within PFDs, since they are alterations in the sensation and/or normal function experienced by a woman during sexual activity and can be classified as disorders of sexual interest/arousal, orgasmic disorder and pelvic-genital pain/penetration disorder. PFDs cause discomfort and reduce the quality of life, including lower participation in physical activity and exercise, with regular and progressive training of the pelvic floor muscles and biofeedback being the treatments of choice, among others.

The PFD are usually associated with events such as childbirth and menopause, however, the increase in the practice of physical activity by the general female population has caused the incidence of UI to rise to 22.9% in young, active, nulliparous women. And the incidence level to rise to 30.7% when we talk about runners and...
reach 45–60% when talking about the marathon distance\(^9,11\). In addition, there are other PFDs that have a higher level of incidence in female runners. Specifically, in the case of POP, 12.7% of female runners reporting having symptoms\(^8\), for AI, the prevalence is quite wide, from 35 to 60%\(^12,13\), 34% of female recreational runners suffer from solid or liquid fecal leaks and gas continence problems. And if we focus only on gas control, the prevalence rises to 29.9%\(^9\). In addition, sexual dysfunctions in the general population reach 30–50% prevalence\(^16\). Similarly, a prevalence of dyspareunia (pain during sexual intercourse) of 20.1% has been described in women who practice intensive sports (+ 8 h of training/week or high level) and 9.4% in women who practice non-intensive sports\(^11\). We also found 57.6% of active women present sexual function problems\(^13\). For all of the above, female runners could be considered a specific risk group for PFD problems.

In the last two decades, the use of Patient-Reported Outcome Measures (PROM)\(^14\) has increased exponentially both in clinical and research environments, since they are economical, reliable and specific tools that allow evaluating subjective aspects that a patient may perceive as altered results of their pathology, such as quality of life, general health, disability, etc. PROMs allow clinicians, researchers and patients to interpret, in a simple way, the results of the evolution of the latter and the changes that occur in their symptoms, capacity and function\(^15\). Likewise, in recent years, the use of scales and questionnaires has been extended to assess aspects of pelvic floor dysfunction and its severity and impact on the quality of life\(^16,17\). Although these questionnaires are very useful, especially in research results, most of them do not cover all aspects of pelvic floor dysfunction: bladder, bowel, prolapse, and symptoms of sexual dysfunction. That is why the Australian Pelvic Floor Questionnaire (APFQ) should be highlighted, which evaluates all pelvic floor symptoms, including bladder, bowel, sexual function, prolapse symptoms, symptom severity, impact on the quality of life and discomfort in women with pelvic floor disorders\(^18\). Despite the widespread cross-cultural validation of the APFQ in pelvic floor dysfunction in other countries\(^9,22\), there is no version of the APFQ validated in Spanish, which is one of the five UN languages\(^23\) and the second most spoken native language in the world\(^24,25\). The adaptation of this tool to Spanish could enable the evaluation of pelvic floor dysfunctions in Spanish-speaking women, regardless of whether or not they perform sports with an impact on the pelvic floor; this would provide objective assessment tools and allow planning therapeutic strategies, for the prevention of pelvic floor dysfunctions and for their treatment once they have been established, which, in turn, can affect the sports performance and quality of life of these women. Consequently, the aim of this study was to carry out a cross-cultural adaptation and psychometric analysis of the Spanish version of the APFQ.

**Methods**

**Study design.** To carry out the cross-cultural adaptation and validation of the Australian Pelvic Floor Questionnaire (APFQ) into Spanish, an observational study divided into two main phases was developed: (1) translation and cross-cultural adaptation, and (2) psychometric tests.

**Participants.** Women runners from all over the Spanish territory, from different federations, clubs and levels were recruited. The inclusion criteria were: (1) Spanish natives over 18 years of age, (2) female runners and (3) more than 6 months practicing running sports. On the other hand, the study excluded: (1) those participants who abandoned the study without answering any of the questions of a questionnaire were excluded, and (2) those who presented a cognitive impairment that did not allow them to understand and/or answer the forms.

**Ethical considerations.** This study was developed following the recommendations of the Declaration of Helsinki in accordance with the ethical principles for research in human beings, and the data were used in accordance with Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights. All participants signed an informed consent to be part of the study. In addition, the Ethics Committee of a Spanish University approved the realisation of this study, with protocol number UVIC-CCC 81/2019.

**Australian Pelvic Floor Questionnaire.** The text of the APFQ questionnaire used in this study consists of 42 questions about the symptoms of PFDs. It has four domains: bladder function (Q1–15), bowel function (Q16–27), prolapse symptoms (Q28–32), and sexual function (Q33–42). The resulting scores were divided by the number of relevant questions within each domain and multiplied by 10, giving a value between 0 and 10 for each of the four domains and an overall score of 40 for pelvic floor dysfunction. Cronbach’s alpha for the four APFQ domains was: bladder function 0.72, bowel function 0.82, pelvic organ prolapse 0.95, and sexual function 0.81\(^18\).

**Translation and cross-cultural adaptation.** To ensure terminological and conceptual equivalence, in the questions that make up the APFQ, the recommendations of the International Test Commission Guidelines for test translation and adaptation were followed\(^26\), as well as those of the World Health Organisation (WHO)\(^27\). The process of the adaptation of the Spanish version of the APFQ from it English version can be broken down into a 5-step protocol: English to Spanish translation of the APFQ, performed by two independent and blinded native Spanish speakers; the two independent versions of the APFQ-Sp were compared and an agreement was reached to develop the preliminary version of the APFQ-Sp; subsequent back-translations (from Spanish to English) were done independently by two native English translators. Any discrepancies in the translation were discussed and resolved by a committee of 5 experts, obtaining a preliminary version. The preliminary version of the APFQ-Sp was subjected to a pilot test, with a sample of 25 participants (Fig. 1).
Questionnaires used for construct validity. Female Sexual Function Index (FSFI). The Female Sexual Function Index (FSFI) questionnaire is a self-administered instrument, consisting of 19 items that refer to the last 4 weeks. These items are grouped into six domains or subscales: sexual desire (items 1 and 2), arousal (items 3, 4, 5, 6), lubrication (items 7, 8, 9, 10), orgasm (items 11, 12, 13), satisfaction (items 14, 15, 16) and pain (items 17, 18, 19). The subscales range from 0 (or 1) to 5, and the sum of the scores of these six subscales yields an overall female sexual function score (with higher scores indicating better sexual function), with a Cronbach's alpha of 0.97 for the total score. In a Spanish version tested in menopausal women, Cronbach's alpha for the total score was 0.964, and in another Spanish version, Cronbach's alpha was 0.85 for the total score.

King Health Questionnaire (KHQ). The King Health Questionnaire measures the impact of urinary incontinence in the physical, social, and mental areas, specifically to assess the quality of life in patients with urinary incontinence. It consists of 21 questions distributed in eight different dimensions, with a scale to measure the severity of urinary symptoms. The range of scores for each dimension goes from 0 (best quality of life) to 100 (worst quality of life), with a Cronbach's alpha above 0.72 in all domains, and the one obtained in the Spanish version was 0.911.

Quality of life SF-12. The SF-12v2 consists of a set of 12 items on health-related quality of life (HRQOL), which shows two reduced scores: on the one hand, the state of the physical component (PCS) and, on the other hand, the state of the mental component (MCS), on a scale of 0 to 100. It also features eight additional domains (physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health).
mental health). Both additional domains and summary scores were calculated using algorithms where each item response has an individual weight in the total score. Higher scores indicate better perceived HRQoL.22

EuroQoL 5-D. EuroQol-5D is a questionnaire to measure people's quality of life. It is made up of 5 domains (mobility, self-care, regular activities, pain/discomfort, and anxiety/depression) divided into three severity levels (no problems, some problems or moderate problems, and serious problems). This system also includes a visual analog scale (EQ-5D VAS) defined by a vertical scale of 10 cm at each end, which are the extreme expressions of self-perceived health status ranging from 0 (worst health) to 100 (best health). Its reliability obtained a Cronbach's α = 0.53.33

Data collection. All participants completed the following questionnaires: The Spanish version of the Australian Pelvic Floor Questionnaire (APFQ-Sp), Female Sexual Function Index (FSFI), King Health Questionnaire (KHQ), EuroQol Quality of Life Questionnaire (5D and VAS), the questionnaire on the general state of health SF-12 (Short form-12) and sociodemographic information. Following the results published in previous studies34,35, in which higher levels of internal consistency and reliability are observed in periods of less than 7 days between the two measurements, the APFQ-Sp was filled twice with a difference of 3–5 days between measurements. The FSFI, KHQ and QoLSF-12 questionnaires were used to analyse the construct validity of the APFQ-Sp. The data were obtained between October 2020 and July 2021. Two blinded researchers external to the study performed the data collection, as well as the data analysis.

Data analysis. A frequency analysis of some of the characteristics of the sample was performed, as well as a descriptive analysis of the sociodemographic variables, including the outcome measures used (APFQ-Sp, IFSE, KHQ, SF-12 and EuroQol5D), calculating the mean and the standard deviation. To analyse the distribution and normality of the sample, the Kolmogorov–Smirnov test was used. Floor and ceiling effect were analysed.

The Cronbach's α coefficients were calculated to analyse the internal consistency of the measures. In addition, the response to the item was analysed using the Intraclass Correlation Index (ICC–2:1). The reliability values were classified according to the following scale: Poor: ≤ 0.40; Moderate: 0.40–0.60; Good: 0.60–0.80; Excellent: ≥ 0.80.36

The formula \( \text{SEM} = s \sqrt{1 - r} \) was used to calculate the standard error of measurement (SEM). For both measures (APFQ-Sp1 and APFQ-Sp2) the test score's standard deviation was "s", and "r" was Pearson's correlation coefficient. Following the analysis described by Stratford37, to measure the sensitivity of the tool, the minimal detectable change 90 (MDC90) was used. The formula used to calculate the MDC90 was as follows: MDC90 = SEM x \( \sqrt{2} \times 1.65 \). The floor or ceiling effect was considered to be present if more than 15% of the participants reached the lowest or highest score, respectively.

The structure and validity of the construct was analysed from the extraction by maximum likelihood (EMV). To maintain the original structure of the APFQ, a 4-factor forced model was performed. In addition, to perform the EMV, the requirement of a minimum of 10 subjects per item was satisfied (minimum number 420 – subjects measured 424).38

Criterion validity was calculated by analysing the degree of correlation between the APFQ-Sp and the Spanish versions of the questionnaires: FSFI16,29, KHQ31, QoLSF-1232 and EuroQoL 5-D33. Pearson's correlation coefficient was structured according to the following scale: r ≤ 0.49 (poor), 0.50 ≤ r ≤ 0.74 (moderate), r ≥ 0.75 (strong)39.

To perform the statistical analysis of this study, the SPSS statistical treatment programme (V.23.0) was used.

Results
Translation and cross-cultural adaptation. The translated and culturally adapted version of the APFQ into Spanish (APFQ-Sp) is presented in Supplementary File S1. The Table 1 shows the anthropometric characteristics of the participants. The total of 424 women who participated in this study had a mean age of 38.56 (± 9.064) years. More than 75% of the participants had a university level of education (bachelor's, master's or doctorate). Almost half of the participants had not had a previous pregnancy. In addition to this, the type of delivery, number of previous abortions, etc., can be analysed in depth. On the other hand, the sports and federative data of the participants are also presented.

Table 2 shows the mean, minimum, maximum and standard deviation values of all the assessment tools used in this study, that is, the Australian Pelvic Floor Questionnaire (APFQ-Sp), the Female Sexual Function Index (FSFI), King Health Questionnaire (KHQ), EuroQol Quality of Life Questionnaire (5D and VAS), the questionnaire on the general state of health SF-12 (Short form-12). Moreover, the values of the different sub-indices or sections in which the different tools are divided are presented. When performing the floor effect and ceiling effect analysis, it was observed that 23 (0.54%) and 16 (0.37%) participants reached the minimum and maximum APFQ-Sp score, respectively. Given these results, the floor/ceiling effects were considered not relevant.

The minimum and maximum values of the APFQ-Sp questionnaire were reached by 1.65% and 4.48% of the participants, respectively, completing the questionnaire in an average time of 18 min. The general internal consistency of the questionnaire was 0.972 and the intraclass correlation coefficient ranged between ICC: 0.596 and 0.972 and the intraclass correlation coefficient ranged between ICC: 0.596 and 0.972. The APFQ-Sp presents a solution of two factors, since they are the only two factors that explain more than 10% of the variance each (18.737% and 12.521%, respectively); however, there is a wide distribution of the variance explained in the APFQ-Sp, since up to question 14 the explained variance exceeds 2% (Table 4). Figure 2 shows the sedimentation graph, while Table 5 shows the load of each of the questions in the two factors that met the established criteria;
|                                      | Frequency | Percentage | Accumulated percentage |
|--------------------------------------|-----------|------------|------------------------|
| **Educational level**                |           |            |                        |
| Compulsory education                 | 20        | 4.7        | 4.7                    |
| Vocational training                  | 64        | 15.1       | 19.8                   |
| University studies                   | 214       | 50.5       | 70.3                   |
| Master                               | 105       | 24.8       | 95.0                   |
| Doctoral studies                     | 21        | 5.0        | 100.0                  |
| **Number of pregnancies**            |           |            |                        |
| 0                                    | 194       | 45.8       | 45.8                   |
| 1                                    | 63        | 14.9       | 60.6                   |
| 2                                    | 116       | 27.4       | 88.0                   |
| 3                                    | 34        | 8.0        | 96.0                   |
| 4                                    | 12        | 2.8        | 98.8                   |
| 5                                    | 3         | 0.7        | 99.5                   |
| 6                                    | 2         | 0.5        | 100.0                  |
| **Number of vaginal deliveries**     |           |            |                        |
| 0                                    | 246       | 58.0       | 58.0                   |
| 1                                    | 67        | 15.8       | 73.8                   |
| 2                                    | 85        | 20.0       | 93.9                   |
| 3                                    | 21        | 5.0        | 98.8                   |
| 4                                    | 4         | 0.9        | 99.8                   |
| 10                                   | 1         | 0.2        | 100.0                  |
| **Number vaginal deliveries suction cup** |        |            |                        |
| 0                                    | 384       | 90.6       | 90.6                   |
| 1                                    | 37        | 8.7        | 99.3                   |
| 2                                    | 2         | 0.5        | 99.8                   |
| 9                                    | 1         | 0.2        | 100.0                  |
| **Number forceps vaginal deliveries** |           |            |                        |
| 0                                    | 392       | 92.5       | 92.5                   |
| 1                                    | 30        | 7.1        | 99.5                   |
| 2                                    | 2         | 0.5        | 100.0                  |
| **Number of episiotomy deliveries**  |           |            |                        |
| 0                                    | 304       | 71.7       | 71.7                   |
| 1                                    | 71        | 16.7       | 88.4                   |
| 2                                    | 45        | 10.6       | 99.1                   |
| 3                                    | 4         | 0.9        | 100.0                  |
| **Number of deliveries with tears**  |           |            |                        |
| 0                                    | 360       | 84.9       | 84.9                   |
| 1                                    | 53        | 12.5       | 97.4                   |
| 2                                    | 10        | 2.4        | 99.8                   |
| 3                                    | 1         | 0.2        | 100.0                  |
| **Cesarean section**                 |           |            |                        |
| 0                                    | 361       | 85.1       | 85.1                   |
| 1                                    | 37        | 8.7        | 93.9                   |
| 2                                    | 25        | 5.9        | 99.8                   |
| 3                                    | 1         | 0.2        | 100.0                  |
| **Number of abortions**              |           |            |                        |
| 0                                    | 334       | 78.8       | 78.8                   |
| 1                                    | 61        | 14.4       | 93.2                   |
| 2                                    | 24        | 5.7        | 98.8                   |
| 3                                    | 4         | 0.9        | 99.8                   |
| 4                                    | 1         | 0.2        | 100.0                  |
| **Federated**                        |           |            |                        |
| Yes                                  | 163       | 38.4       | 38.4                   |
| No                                   | 261       | 61.6       | 100.0                  |
| **Level of competition**             |           |            |                        |
| Provincial                           | 81        | 19.1       | 19.1                   |
| Regional                             | 76        | 17.9       | 37.0                   |
| National                             | 44        | 10.4       | 47.4                   |
| International                        | 17        | 4.0        | 51.4                   |
| I don't do competitions              | 206       | 48.6       | 100.0                  |
| **Practice of another sport activity** |         |            |                        |
| Yes                                  | 331       | 78.1       | 78.1                   |
| No                                   | 93        | 21.9       | 100.0                  |
| Continued                            |           |            |                        |
specifically, in factor 1, questions 33–41 exceeded 0.5 of load factor, while in the second factor, questions 4, 5, 6, 14, 15, 29 and 32 exceeded this value.

When analysing the correlation between the total value of the APFQ-Sp and its sub-scales, it is observed that the levels of correlation oscillate between $r = 0.103$ (Defecation Section – Sexual Activity Section) and $r = 0.752$ (Total APFQ – Sexual Activity Section) (Table 6). In addition, in the calculation of the criterion validity (Table 6), significant correlation values were obtained, with a range of $r = 0.285–0.776$ in FSFI, $r = 0.103–0.778$ in KHQ, $r = 0.122–0.872$ in SF-12 and $r = 0.384–0.817$ in EuroQoL. The rest of the correlation values are presented in Table 6.

**Discussion**

This study aimed to carry out a cross-cultural adaptation and a validation study of the tool for the assessment and monitoring of pelvic floor dysfunction APFQ into Spanish. The translation and cross-cultural adaptation of the APFQ-Sp was carried out following the recommendations of the literature, which ensures the conceptual equivalence between the translated version and the original version and it is essential to facilitate the use of the APFQ-Sp among Spanish speakers, while favouring the comparison of potential results with versions of the APFQ published in other languages. Based on the cross-cultural adaptation process carried out, the APFQ-Sp proved to be an understandable and easy-to-use tool.

**Translation of the APFQ to APFQ‑SP and cross‑cultural adaptation.** In addition to the original version of the APFQ, other versions of the APFQ have been published, such as the Turkish, Chinese, Arabic, Serbian and German versions. Both the translation from the original version to the Spanish version and the back-translation were carried out by native translators to guarantee the equivalence of the terms between both versions, which facilitates its use among researchers and clinician Spanish speakers.

**Construct validity.** To assess the construct validity, the structure of the original version of the APFQ was taken into account, where 4 factors are identified. In this sense, two factors explain a level of variance greater than 10% and, in addition, in the scree plot they show a change in proportion in the level of explained variance. In this sense, if all the criteria that are usually considered for factor extraction had been taken into account (>10% of the variance, eigenvalue >1.0, and scree plot inflection point), two factors of APFQ-Sp would have been extracted. In this sense, the only version whose construct validity has been analysed is the Arabic version, which shows values of KMO = 0.806 and Bartlett sphericity test = 4150.46. It would be interesting to carry out studies to analyse the construct validity of the rest of the versions and determine whether they behave in a similar way as the versions that have performed such analysis (Spanish and Arabic).

**Internal consistency and test–retest.** The internal consistency in the APFQ-Sp showed a Cronbach’s $\alpha$ of 0.972, and, in the sub-scales, it ranged between Cronbach’s $\alpha = 0.828$ (sexual activity section) and 0.935 (urinary tract section) (Table 3). These values are slightly higher than those observed in the Arabic (0.877), Chinese (0.83–0.89), Serbian (0.822–0.846) and Turkish (0.733–0.858) versions and original version (0.74–1.00), although all except one dimension from the Turkish version and one from the original version are considered to have excellent internal consistency.

| Practice of another sport activity | Frequency | Percentage | Accumulated percentage |
|-----------------------------------|-----------|------------|------------------------|
| None                              | 88        | 20.8       | 20.8                   |
| Pilates, abdominal work, yoga, stretching | 16        | 3.8        | 24.5                   |
| Functional training               | 21        | 5.0        | 29.5                   |
| Impact sports                     | 13        | 3.1        | 32.5                   |
| Cardio sports                     | 140       | 33.0       | 65.6                   |
| Strength                          | 44        | 10.4       | 75.9                   |
| Combination of 2 or more          | 102       | 24.1       | 100.0                  |

| Specific pelvic floor work        |           |            |                        |
|-----------------------------------|-----------|------------|------------------------|
| Hypopressives                     | 57        | 13.4       | 13.4                   |
| Kegel exercises                   | 23        | 5.4        | 18.9                   |
| 5P Method                         | 4         | 0.9        | 19.8                   |
| I do not do any specific work     | 285       | 67.2       | 87.0                   |
| Other                             | 12        | 2.8        | 89.9                   |
| Hypopressives + Kegel             | 31        | 7.3        | 97.2                   |
| Hypopressives + other             | 5         | 1.2        | 98.3                   |
| Hypopressives + Kegel + 5P        | 4         | 0.9        | 99.3                   |
| Kegel + 5P                        | 2         | 0.5        | 99.8                   |
| Kegel + other                     | 1         | 0.2        | 100.0                  |

Table 1. Characteristics of the study population.
When the test–retest values are compared, since the APFQ-Sp has ICC values that range between 0.596 and 0.960 (Table 3), it is observed that they are consistent with the Arabic version21, which presents ICC values: 0.500–0.833. However, these values are slightly lower than those observed in the Serbian (ICC: 0.896–0.944) 19, Turkish (ICC: 0.876–0.954)22, and original version (ICC: 0.74–1.0) 18, and greater than some dimensions of the Chinese version (ICC: 0.22–0.88)20,40.

**Criterion validity.** The values observed in the criterion validity when comparing the APFQ-Sp with the rest of the questionnaires (FSFI, KHQ, SF-12, EuroQol_5D, EuroQol_V AS) and their different subdimensions show

| Years | Minimum | Maximum | Mean | Standard deviation |
|-------|---------|---------|------|--------------------|
| Total | 18      | 67      | 38.56| 9.064              |

| Urinary tract section | Defecatory section | Prolapse section | Sexual activity section | Total |
|-----------------------|--------------------|------------------|------------------------|-------|
| Cronbach’s Alpha | 0.935               | 0.919            | 0.885                  | 0.828            | 0.972 |
| ICC (item responses) | 0.596–0.960         |                  |                        |                   |
that the total value of the questionnaire tends to correlate better with all the reference questionnaires in comparison with the dimensions of the APFQ-Sp. In this sense, when the results are compared with other versions, it is observed that, with the exception of the original version, the APFQ-Sp is the only one that evaluated this psychometric aspect. The original version performs a convergence analysis with the short version of the Urogenital Distress Inventory (SUDI), showing correlation levels of $r = 0.80$, while the level of correlations between pelvic organ prolapse and prolapse symptoms quantification measurements (measured in 106 patients) showed a range of $r = 0.25–0.68$. In this sense, it is observed that the APFQ complements very well with other questionnaires or diagnostic instruments for patients with pelvic floor problems, although it would be interesting to know the level of correlation of the other versions to have a much more complete perspective.

**Implications for future research.** There is a need for developing valid and reliable instruments to measure pelvic floor dysfunctions in order to provide accurate and consistent measurements over time\(^{42,43}\). These instruments must be concise, valid, reliable, evidence-based and developed using best practices\(^{42,43}\). In this context, the APFQ is a measure that was proposed to evaluate pelvic floor dysfunctions in women\(^{18}\). The APFQ was developed based on the most valid and reliable questions to focus on the main pelvic floor dysfunctions in women through a systematic review of the literature to identify measures with the best psychometric properties. This study provides evidence for the validity of the APFQ-Sp. In this sense, the APFQ-Sp is a concise, valid, reliable and evidence-based document and, at the same time, it is an instrument developed using best practices. Therefore, the APFQ-Sp is a measure that can be recommended for the assessment of pelvic floor dysfunction in Spanish female runners.

### Table 4. Total variance explained by the four factors extracted according to the structure of the original APFQ.

| Component | Initial eigenvalues | Sums of extraction of charges squared |
|-----------|---------------------|---------------------------------------|
| 1         | 7.870               | 18.737                                |
| 2         | 5.259               | 12.521                                |
| 3         | 2.818               | 6.708                                 |
| 4         | 2.453               | 5.840                                 |
| 5         | 2.104               | 5.008                                 |
| 42        | 0.043               | 0.103                                 |

| Component | Total Variance % | % accumulated | Total Variance % | % accumulated |
|-----------|------------------|---------------|------------------|---------------|
| 1         | 18.737           | 18.737        | 18.737           | 18.737        |
| 2         | 12.521           | 31.259        | 5.259            | 12.521        |
| 3         | 6.708            | 37.967        | 2.818            | 6.708         |
| 4         | 5.840            | 43.807        | 2.453            | 5.840         |
| 5         | 5.008            | 48.816        | 2.104            | 5.008         |
| 42        | 0.103            | 100.000       | 0.043            | 0.103         |

**Figure 2.** Sedimentation graph.
The current study demonstrates that the APFQ-Sp is a valid measure to assess pelvic floor dysfunction in the Spanish population, which allows researchers and clinicians to use this tool within both clinical and research settings. In this sense, research on the pelvic floor is an area of special interest, since it has implications for the development of interventions for both the prevention and treatment of pelvic floor dysfunctions in the female population. In addition, future research should study the APFQ in different clinical populations, such as cancer related to the pelvic floor, or analyse some psychometric variables that have not been taken into account in this validation study, and that are linked to longitudinal studies, such as the sensitivity to change.

**Strengths and weaknesses.** This study presents some strengths that show the appropriateness of its execution. The main strength is that it allows the APFQ to be adapted into Spanish, the second most widely spoken language in the world and one of the five official languages of the UN. On the one hand, this cross-cultural adaptation of the APFQ-Sp is a clear indication of its multidisciplinary application. However, this study presents some weaknesses that should be addressed in future research. One of them is the lack of information about the gender distribution of the participants. The sample consists primarily of women, which limits the generalizability of the results to the male population. Additionally, the sample size is relatively small, which may affect the reliability of the findings.

Table 5. Load factor of the 4 factors extracted from an exploratory factor analysis. Significant values are in bold.

| Component | 1  | 2  | 3  | 4  |
|-----------|----|----|----|----|
| 1. How many times do you pass urine in the day? | 0.095 | 0.228 | -0.038 | -0.195 |
| 2. How many times do you get up at night to pass urine? | 0.186 | 0.268 | 0.138 | -0.291 |
| 3. Do you wet the bed before you wake up? | 0.029 | 0.201 | -0.102 | -0.002 |
| 4. Do you need to rush/hurry to pass urine when you get the urge? | 0.204 | 0.518 | -0.114 | -0.302 |
| 5. Does urine leak when you rush/hurry to the toilet/Can you make it in time? | 0.191 | 0.509 | -0.178 | -0.206 |
| 6. Do you leak with coughing, sneezing, laughing, exercising? | 0.165 | 0.601 | -0.136 | -0.058 |
| 7. Is your urinary stream/flow weak/prolonged/slow? | 0.188 | 0.433 | -0.029 | -0.092 |
| 8. Do you have a feeling of incomplete bladder emptying? | 0.215 | 0.465 | 0.027 | -0.209 |
| 9. Do you need to strain to empty your bladder? | 0.129 | 0.393 | 0.057 | -0.159 |
| 10. Do you have to wear pads? | 0.057 | 0.483 | -0.130 | -0.183 |
| 11. Do you limit your fluid intake to decrease leakage? | 0.186 | 0.412 | -0.086 | -0.308 |
| 12. Do you have frequent bladder infections? | -0.019 | 0.194 | 0.150 | -0.139 |
| 13. Do you have pain in your bladder/urethra when you empty your bladder? | 0.035 | 0.307 | 0.029 | -0.309 |
| 14. Does urine leakage affect your routine activities (recreation, shopping etc.) | 0.222 | 0.519 | -0.165 | -0.151 |
| 15. How much of a bother is your bladder problem to you? | 0.164 | 0.692 | -0.150 | -0.143 |
| 16. How often do you usually open your bowels? | -0.020 | 0.154 | 0.421 | 0.324 |
| 17. How is the consistency of your usual stool? | -0.018 | -0.011 | 0.042 | -0.023 |
| 18. Do you have to strain a lot to empty your bowels? | 0.120 | 0.197 | 0.653 | 0.342 |
| 19. Do you use laxatives to empty your bowels? | 0.000 | 0.110 | 0.395 | 0.181 |
| 20. Do you feel constipated? | 0.129 | 0.217 | 0.715 | 0.267 |
| 21. When you get wind/latus, can you control it or does wind leak? | 0.186 | 0.316 | 0.256 | -0.189 |
| 22. Do you get an overwhelming sense of urgency to empty bowels? | 0.146 | 0.269 | 0.187 | -0.309 |
| 23. Do you leak watery stool when you don’t mean to? | 0.205 | 0.355 | 0.113 | -0.110 |
| 24. Do you leak normal stool when you don’t mean to? | 0.130 | 0.295 | 0.114 | -0.235 |
| 25. Do you have the feeling of incomplete bowel emptying? | 0.248 | 0.299 | 0.508 | 0.082 |
| 26. Do you use finger pressure to help empty your bowel? | 0.143 | 0.072 | 0.417 | 0.188 |
| 27. How much of a bother is your bowel problem to you? | 0.200 | 0.402 | 0.578 | 0.044 |
| 28. Do you get a sensation of tissue protrusion in your vagina/lump/ bulging? | 0.135 | 0.479 | -0.376 | 0.604 |
| 29. Do you experience vag. pressure/ heaviness/dragging sensation? | 0.162 | 0.530 | -0.200 | 0.396 |
| 30. Do you have to push back your prolapse in order to void? | 0.140 | 0.405 | -0.381 | 0.551 |
| 31. Do you have to push back your prolapse to empty your bowels? | 0.082 | 0.272 | -0.098 | 0.281 |
| 32. How much of a bother is the prolapse to you? | 0.115 | 0.519 | -0.311 | 0.569 |
| 33. Are you sexually active? If not sexually active, please answer questions 34 and 42 only | -0.771 | 0.210 | 0.103 | -0.081 |
| 34. If NOT, why not: | -0.861 | 0.306 | 0.010 | 0.023 |
| 35. Do you have sufficient lubrication during intercourse? | 0.916 | -0.278 | -0.024 | 0.002 |
| 36. During intercourse vaginal sensation is: | 0.932 | -0.212 | -0.032 | 0.006 |
| 37. Do you feel that your vagina is too loose or lax? | 0.906 | -0.121 | -0.082 | -0.032 |
| 38. Do you feel that your vagina is too tight? | 0.911 | -0.273 | -0.005 | 0.006 |
| 39. Do you experience pain with intercourse: | 0.934 | -0.228 | -0.001 | 0.002 |
| 40. Where does the pain occur | 0.775 | -0.124 | 0.007 | 0.024 |
| 41. Do you leak urine during sex? | 0.924 | -0.256 | -0.054 | -0.010 |
| 42. How much of a bother are these sexual issues to you? | 0.367 | 0.320 | 0.019 | 0.156 |
adaptation and validation benefits the entire Spanish-speaking clinical population, and, on the other hand, the results obtained with this instrument can be compared with other population groups that have used other versions, such as the original (English)\textsuperscript{18}, Turkish\textsuperscript{22}, Arabic\textsuperscript{21}, Serbian\textsuperscript{19} and Chinese\textsuperscript{20,40} versions. In addition, the cross-cultural adaptation and the subsequent validation study were carried out respecting the minimum number of subjects recommended in the literature\textsuperscript{38}. In this sense, there would be 420 minimum necessary subjects, and it was carried out with 424 participants.

However, there are some weaknesses that must be taken into account when interpreting the results of this study. Specifically, this study did not perform the psychometric analysis of longitudinal variables, such as error scores, responsiveness or sensitivity to change. In this sense, future studies should be designed and executed in order to assess these psychometric variables in the APFQ-SP.

The cross-cultural adaptation and validation of the APFQ-SP has been carried out in a specific group of women with a higher level of incidence of PFDs. However, there are other population groups that also have a higher incidence of PFDs, such as multiparous women or women over 65 years of age, so future studies should be designed to validate the APFQ in these specific population groups.

### Conclusions

The Spanish version of the APFQ is a valid and reliable measure that can be used clinically to assess pelvic floor dysfunctions in the Spanish female population. This instrument is complete and includes different dimensions on the most relevant aspects and symptoms of female pelvic floor dysfunctions, allowing its use by both researchers and clinical professionals, who speak Spanish, for the evaluation and follow-up of patients with pelvic floor dysfunctions.

### Table 6. Correlation matrix between the APFQ-Sp, its different dimensions and the IFSF, KHQ, SF-12 and EuroQoL-5D questionnaires.

|            | Total | Urinary tract section | Defecatory section | Prolapse section | Sexual activity section |
|------------|-------|-----------------------|--------------------|------------------|------------------------|
| APFQ       |       |                       |                    |                  |                        |
| Total      | 1     | Good                  | Moderate           | Moderate         | Good                   |
| Urinary tract section | 0.649** | 1                     | Poor               | Poor             | Poor                   |
| Defecatory section | 0.532** | 0.290**               | 1                  | Poor             | Poor                   |
| Prolapse section | 0.550** | 0.330**               | 0.122*             | 1                | Poor                   |
| Sexual activity section | 0.752** | 0.207**               | 0.103*             | 0.192**          | 1                      |
| FSI        |       |                       |                    |                  |                        |
| FSFI_Total_punctuation | 0.776** | 0.485**               | 0.421**            | 0.404**          | 0.601**                |
| FSFI orgasm domain | 0.605** | 0.398**               | 0.346**            | 0.319**          | 0.450**                |
| FSFI satisfaction domain | 0.523** | 0.335**               | 0.285**            | 0.320**          | 0.576**                |
| FSFI_Pain domain | 0.575** | 0.332**               | 0.289**            | 0.375**          | 0.438**                |
| KHQ        |       |                       |                    |                  |                        |
| Q1. How would you describe your general health? | 0.616** | 0.425**               | 0.328**            | 0.329**          | 0.455**                |
| Q2. To what extent do you think your urinary problems affect your life? | 0.572** | 0.535**               | 0.259**            | 0.342**          | 0.351**                |
| KHQ Part 1 | 0.778** | 0.621**               | 0.387**            | 0.437**          | 0.531**                |
| KHQ role limitation | 0.516** | 0.400**               | 0.265**            | 0.281**          | 0.359**                |
| KHQ physical limitation | 0.478** | 0.523**               | 0.179**            | 0.283**          | 0.272**                |
| KHQ social limitation | 0.538** | 0.402**               | 0.307**            | 0.333**          | 0.349**                |
| KHQ personal relationships | 0.426** | 0.334**               | 0.103**            | 0.227**          | 0.361**                |
| KHQ emotions | 0.489** | 0.491**               | 0.087              | 0.441**          | 0.287**                |
| KHQ sleep energy | 0.326** | 0.358**               | 0.156**            | 0.249**          | 0.140**                |
| KHQ severity | 0.470** | 0.598**               | 0.232**            | 0.263**          | 0.197**                |
| KHQ Part 2 | 0.616** | 0.701**               | 0.207**            | 0.386**          | 0.339**                |
| KHQ Part 3 | 0.548** | 0.650**               | 0.269**            | 0.293**          | 0.262**                |
| SF-12      |       |                       |                    |                  |                        |
| Physical function | 0.684** | 0.506**               | 0.367**            | 0.338**          | 0.496**                |
| Role physical | 0.702** | 0.476**               | 0.394**            | 0.350**          | 0.522**                |
| Bodily pain | 0.769** | 0.510**               | 0.413**            | 0.402**          | 0.580**                |
| General health | 0.728** | 0.492**               | 0.438**            | 0.274**          | 0.569**                |
| Vitality | 0.082 | 0.098*                | 0.030              | 0.039          | 0.047                  |
| Social functioning | 0.708** | 0.422**               | 0.380**            | 0.448**          | 0.512**                |
| Role emotional | 0.217** | 0.143**               | 0.090              | 0.122**          | 0.175**                |
| Mental health | 0.159** | 0.142**               | 0.058              | 0.043          | 0.135**                |
| Physical component state | 0.786** | 0.538**               | 0.422**            | 0.389**          | 0.595**                |
| Mental component state | 0.872** | 0.622**               | 0.546**            | 0.418**          | 0.606**                |
| EuroQoL_5D | 0.817** | 0.537**               | 0.405**            | 0.443**          | 0.630**                |
| EuroQoL VAS | 0.720** | 0.435**               | 0.391**            | 0.384**          | 0.561**                |
Data availability

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Received: 28 February 2022; Accepted: 5 May 2022
Published online: 18 May 2022

References

1. Mandimika, C. L. et al. Knowledge of pelvic floor disorders in a population of community-dwelling women. Am. J. Obstet. Gynecol. 210(165), e1-165.e9 (2014).
2. Woodley, S. J., Boyle, R., Cody, J. D., Merkved, S. & Hay-Smith, E. J. C. Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst. Rev. 2017, 14651858 (2017).
3. Lipschuetz, M. et al. Degree of bother from pelvic floor dysfunction in women one year after first delivery. Eur. J. Obstet. Gynecol. Reprod. Biol. 191, 90–94 (2015).
4. Dieter, A. A., Wilkins, M. F. & Wu, J. M. Epidemiological trends and future care needs for pelvic floor disorders. Curr. Opin. Obstet. Gynecol. 27, 380–385 (2015).
5. Kolberg-Tennfjord, M. et al. Effect of postpartum pelvic floor muscle training on vaginal symptoms and sexual dysfunction - Secondary analysis of a randomised trial. BJOG An Int. J. Obstet. Gynaecol. 123, 634–642 (2016).
6. Skinner, E. M., Barnett, B. & Dietz, H. P. Psychological consequences of pelvic floor trauma following vaginal birth: A qualitative study from two Australian tertiary maternity units. Arch. Womens. Ment. Health 21, 341–351 (2018).
7. Hagen, S. et al. Effectiveness of pelvic floor muscle training with and without electromyographic biofeedback for urinary incontinence in women: Multicentre randomised controlled trial. BJM 371, 1–11 (2020).
8. Chmielewska, D. et al. Electromyographic characteristics of pelvic floor muscles in women with stress urinary incontinence following eSMG-assisted biofeedback training and Pilates exercises. PLoS ONE 14, 1–22 (2019).
9. Forner, L. S., Beckman, E. M. & Smith, M. D. Do women runners report more pelvic floor symptoms than women in CrossFit®? A cross-sectional survey. Int. Urogynecol. J. 32, 295–302 (2020).
10. Skinner, E. M., Barnett, B. & Dietz, H. P. Psychological consequences of pelvic floor trauma following vaginal birth: A qualitative study from two Australian tertiary maternity units. Arch. Womens. Ment. Health 21, 341–351 (2018).
11. Verbeek, M. & Hayward, L. Pelvic floor dysfunction and its effect on quality of sexual life. Eur. J. Obstet. Gynecol. Reprod. Biol. 191, 90–94 (2015).
12. Cerruto, M. A. An introduction to patient-reported outcome measures (PROMs) in physiotherapy. Minerva Urol. Nefrol. 72, 698–711 (2020).
13. UchôaLeitãoCabral, P. Knowledge of pelvic floor disorders in a population of community-dwelling women. Int. J. Environ. Res. Public Health 17, 1–13 (2020).
14. Sánchez-Sánchez, B. et al. Quality of life in POP: Validity, reliability and responsiveness of the Prolapse Quality of Life Questionnaire (P-QoL) in Spanish women. Int. J. Environ. Res. Public Health 17, 1690 (2020).
15. Baessler, K., O’Neill, S. M., Maher, C. F. & Battistutta, D. Australian pelvic floor questionnaire: A validated interviewer-administered pelvic floor questionnaire for routine clinical practice. Int. Urogynecol. J. 20, 149–158 (2009).
16. Sánchez-Sánchez, B. et al. Lower urinary tract and gastrointestinal dysfunction in sportswomen: A systematic review and meta-analysis of observational studies. Minerva Urol. Nefrol. 72, 698–711 (2020).
17. Kyte, D. G. et al. An introduction to patient-reported outcome measures (PROMs) in physiotherapy. Physioterapia (United Kingdom) 101, 119–125 (2015).
18. Sánchez-Sánchez, B. et al. Quality of life in POP: Validity, reliability and responsiveness of the Prolapse Quality of Life Questionnaire (P-QoL) in Spanish women. Int. J. Environ. Res. Public Health 17, 1690 (2020).
19. Rosen, R. A. et al. Female sexual function index: A multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 26, 191–205 (2000).
20. Perez-Herrezuelo, I. et al. The female sexual function index: Reliability and validity in Spanish postmenopausal women. Menopause J. N. Am. Menopause Soc. 26, 401–408 (2019).
21. World Health Organization. The female sexual function index: A multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 26, 191–205 (2000).
22. World Health Organization. The female sexual function index: Reliability and validity in Spanish postmenopausal women. Menopause J. N. Am. Menopause Soc. 26, 401–408 (2019).
23. World Health Organization. The female sexual function index: Reliability and validity in Spanish postmenopausal women. Menopause J. N. Am. Menopause Soc. 26, 401–408 (2019).
24. Kelleher, C. J., Cardozo, L. D., Khullar, V. & Salvatore, S. A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. 104, 1374–1379 (1997).
25. Romero-Cullerés, G., Sánchez-Raya, J., Conejero-Sugranyes, J. & González-Viejo, M. A. Validación de la versión española del cuestionario King’s Health para la evaluación de la calidad de vida relacionada con la incontinencia urinaria en pacientes con lesión medular. Med. Clin. (Barc) 137, 491–494 (2011).
26. Ware, J., Kosinski Jr, M., Turner-Bowker, D. & Gandek, B. How to Score Version 2 of the SF-12 Health Survey (with a Supplement Documenting Version 1). (QualityMetric Incorporated, Health Assessment Lab, 2002).
27. López-Alonso, S. R., Navarro-Casado, F., González-Rojo, J., Martínez-Sánchez, C. M. & Romero-Cañadillas, A. B. Validez, fiabi- lidad y convergencia de COOP/WONCA y EUROQoL, administrados telefónicamente, en población con osteoartrosis de cadera y rodilla. Index Enferm. 18, 133 (2009).
28. Marx, R. G., Menezes, A., Horovitz, L., Jones, E. C. & Warren, R. F. A comparison of two time intervals for test-retest reliability of health status instruments. J. Clin. Epidemiol. 56, 730–735 (2003).
29. Kelleher, C. J., Cardozo, L. D., Khullar, V. & Salvatore, S. A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. 104, 1374–1379 (1997).
30. Shrout, P. E. & Fleiss, J. L. Intraclass correlations: Uses in assessing rater reliability. Psychol. Bull. 86, 420–428 (1979).
37. Stratford, P., Gill, C., Westaway, M. & Binkley, J. Assessing disability and change on individual patients: A report of a patient specific measure. Physiother. Canada 47, 258–263 (1995).
38. Costello, A. B. & Osborne, J. W. Best practices in exploratory factor analysis: Four recommendations for getting the most from your analysis. Pract. Assess. Res. Eval. 10, 1–9 (2005).
39. Field, A. Discovering Statistics Using SPSS. (2009).
40. Hou, Y. & Tong, B. Three-year follow-up of a self-administered Australian pelvic floor questionnaire validated in Chinese pregnant and postpartum women. Int. Urogynecol. J. https://doi.org/10.1007/s00192-022-05077-w (2022).
41. Schoenfeld, M. et al. Sexuality in German urogynecological patients and healthy controls: Is there a difference with respect to the diagnosis? Eur. J. Obstet. Gynecol. Reprod. Biol. 170, 567–570 (2013).
42. Guallar-Bouloc, M. et al. Spanish questionnaires for the assessment of pelvic floor dysfunctions in women: A systematic review of the structural characteristics and psychometric properties. Int. J. Environ. Res. Public Health 18, 1–18 (2021).
43. Gray, T. G., Vickers, H., Krishnaswamy, P. & Jha, S. A systematic review of English language patient-reported outcome measures for use in urogynaecology and female pelvic medicine. Int. Urogynecol. J. 32, 2093 (2021).

Author contributions
A.G.M. and G.M.T. conceived the study, and all authors participated in the study design. M.G.B., A.G.M. and G.M.T. collected the data. M.G.S. analysed the data. M.G.S., G.M.T. and M.G.B. drafted the manuscript. A.G.M., M.K.J., G.M.T., M.G.B., M.G.S. and J.A.M.B. writing, review and editing. AGM founding acquisition. All authors gave comments on the earlier versions of the manuscript. All authors edited the manuscript and approved the final version.

Funding
This research and the APC were partially funded by the Erasmus + Strategic Partnership for Higher Education Programme (Key Action 203), grant number 2018-1-PL01-KA203-051055.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-12043-5.

Correspondence and requests for materials should be addressed to A.G.-M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022